Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
Chronic tendinopathy — the painful, persistent degeneration of a tendon that has not healed after months of rest, physiotherapy, NSAIDs, or injections — is one of the most-studied targets for regenerative medicine. This page reviews, conservatively, where the published evidence for mesenchymal stem cell (MSC) therapy actually stands for tendinopathy, who is and is not a candidate, and how the COFEPRIS-regulated clinical model at Regeneris in Cancún, México works from your first evaluation onward.
Chronic tendinopathy is a degenerative, not just inflammatory, tendon disease — and several peer-reviewed clinical studies (patellar, Achilles, rotator cuff, lateral epicondylitis) show that mesenchymal stem cell therapy can improve pain, function, and tendon structure in cases that have failed conservative care. The evidence is still investigational for most indications, outcomes are individual, and candidacy depends on imaging, history, and goals. At Regeneris in Cancún, México the protocol is a free medical evaluation first, then a personalized written quote — no online prices, no guarantees, COFEPRIS-regulated.
Clinical overview
Tendinopathy is a degenerative condition of the tendon — not a simple inflammation. After repeated overuse, the collagen architecture of the tendon disorganizes, neovessels invade, the tenocyte population shifts, and the tendon thickens and becomes painful. When pain and dysfunction persist for more than three to six months despite physiotherapy, eccentric loading, NSAIDs, and at least one course of injections, the condition is usually called chronic tendinopathy — and is what most published regenerative-medicine trials enroll. The most commonly studied tendons are the patellar (jumper's knee), the mid-portion Achilles, the rotator cuff (especially supraspinatus), and the lateral elbow (extensor carpi radialis brevis / tennis elbow).
What the published evidence shows
"Regenerative" is not one evidence category. Several peer-reviewed studies — randomized in some cases, single-arm in others — report meaningful improvement in pain, function, and tendon structure with mesenchymal stem cell therapy for chronic tendinopathy that has failed conservative care. None of the studies below promises a cure; they describe a clinical signal that justifies further investigation. Read them as the published facts — not as a guarantee for any individual case in Cancún or anywhere else.
A double-blind, randomized study in chronic patellar tendinopathy with a focal lesion greater than 3 mm reported that autologous bone-marrow-derived MSCs produced greater structural improvement of the tendon at 6 months than leukocyte-poor PRP — a direct active-control comparison rather than a placebo-only design.
A phase-IIa, single-arm, proof-of-concept trial of autologous bone-marrow-derived MSCs in 10 adults with chronic non-insertional Achilles tendinopathy reported no serious adverse events at 24 weeks and clinically meaningful improvement in VISA-A and MOXFQ Pain scores in the majority of patients — supporting safety and an early efficacy signal.
Who is and isn't a candidate
Not everyone with tendon pain is a candidate for MSC therapy, and saying so up front is part of practicing medicine honestly. Below is how the medical team in Cancún typically thinks about candidacy. The final determination is always made in person, after imaging and history, never from a website.
Regulatory framework
Regenerative therapy in México is not a grey market — it is federally regulated by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the Mexican equivalent of the U.S. FDA. Regeneris Therapy operates in Cancún, Quintana Roo, México, under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053. Our laboratory chain documents cell sourcing, viability, and traceability for every lot used in tendinopathy protocols.
Aviso Sanitario and Aviso de Publicidad on file with COFEPRIS — the same federal authority that regulates every legitimate medical procedure in México. Our Cancún clinic is included on that paper trail.
Our approach
The Regeneris model for chronic tendinopathy starts with a free, no-obligation medical evaluation — not a price. After that evaluation, you receive a personalized written quote outlining a candidate protocol. We do not publish prices online, by policy, because every tendinopathy case is individual: tendon, lesion size, prior treatments, comorbidities, and goals all change the plan.
Submit your history, recent imaging (ultrasound or MRI of the affected tendon), prior treatments, and goals. A Regeneris physician in Cancún reviews your case and tells you honestly whether MSC therapy is reasonable — or whether you should pursue a different path first.
If you are a candidate, your physician designs the protocol: cell source (autologous vs allogeneic), dose, route of administration (intratendinous under ultrasound guidance vs systemic IV vs combined), adjuncts, and the follow-up plan over 3–12 months.
Only after evaluation do you receive a written quote tailored to your case. There are no online price lists for tendinopathy because there is no one-size-fits-all protocol — and we won't pretend otherwise.
Realistic expectations
Pain and function rarely change overnight after a MSC injection for tendinopathy. Published trials report gradual change: meaningful pain and function improvement at 12–24 weeks, with structural change on ultrasound or MRI typically lagging behind symptom change. Some patients respond well, some respond partially, and some do not respond — that variance is honest and is what the published data shows.
Most published patellar, Achilles, and elbow MSC studies measure clinically meaningful change at 12–24 weeks, with continued change tracked out to 12 months. We plan follow-up on that same scale.
Validated outcomes — VISA-P (patellar), VISA-A (Achilles), VAS pain, MOXFQ — improve in the majority of published patients. Structural improvement on ultrasound/MRI is also reported, especially for focal lesions.
FAQ
What patients with chronic tendinopathy ask us most when considering MSC therapy at our Cancún, México clinic.
The honest answer is: published evidence shows a real clinical signal for several tendinopathy indications — patellar, Achilles, rotator cuff, and lateral epicondylitis — with improvements in pain, function, and tendon structure compared to baseline or to active controls such as PRP. The level of evidence still places MSC therapy as investigational for most tendinopathy indications, not as established standard care. Your individual response depends on the tendon, the lesion, your history, and your goals. The Regeneris physicians in Cancún will quote the cited papers to you directly and tell you honestly whether your case is the kind that has been studied.
Continue exploring
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for chronic tendinopathy is investigational for most indications, and outcomes vary by tendon, lesion, patient history, and protocol. The choice of cell source, dose, and route is a medical decision that requires an individualized evaluation with a licensed physician in Cancún, México; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent imaging (ultrasound or MRI), and a short summary of what you've tried. A Regeneris physician in Cancún, México will review your case and tell you honestly whether MSC therapy is a reasonable next step — with a personalized written quote after your free medical evaluation.
That biology matters for therapy choice. Because chronic tendinopathy is structural and degenerative — not simply inflamed — strategies that only suppress inflammation tend to plateau, which is why regenerative approaches that aim to restore the repair environment are being studied so actively.
A pilot study of allogeneic adipose-derived MSCs in chronic lateral epicondylitis (n=12) reported VAS pain dropping from ~67 to ~15 mm and a near-doubling of elbow performance scores over 52 weeks, with sonographic reduction of the tendon defect and no significant safety signals — the first clinical demonstration of MSC benefit in chronic tennis elbow.
A systematic review and meta-analysis of prospective clinical studies of MSC therapy for tendon disorders concluded that MSC injection may improve pain, function, and radiological/arthroscopic parameters, while explicitly calling for larger randomized trials before MSC therapy can be considered established care for any tendinopathy indication.
The field's own founding figure reframed MSCs as 'medicinal signaling cells,' arguing that their therapeutic effect comes mainly from secreted paracrine factors that modulate inflammation and recruit local progenitors — the mechanistic basis for most MSC tendinopathy protocols today, including the ones we use in Cancún.
The honest summary: for chronic tendinopathy that has failed conservative care, MSC therapy is supported by a real and growing clinical literature — but the level of evidence still places it as investigational for most indications. We do not market it as a guaranteed cure, and we encourage every patient to read the cited papers themselves before deciding.
Each MSC lot used at Regeneris in Cancún is documented from donor screening through expansion, viability testing, and release criteria — the prerequisites for any honest tendinopathy protocol.
Every plan is built by a licensed Mexican physician at our Cancún clinic; cell sourcing, dose, route (intratendinous vs systemic), and follow-up cadence are individualized in writing.
Being in Cancún is a logistical advantage as well as a regulatory one: direct flights from most major US and Canadian hubs, a fully accredited medical-tourism destination, and an English-Spanish bilingual clinical team — none of which substitutes for evidence, but all of which makes the in-person evaluation realistically accessible.
If you proceed, the procedure happens at the Cancún clinic under physician supervision, with structured follow-up at defined intervals so that pain, function, and (when relevant) ultrasound or MRI structure can be reassessed honestly.
MSC therapy does not regrow a fully ruptured tendon, does not replace surgery when surgery is indicated, and is not a guaranteed cure. Anyone promising a guaranteed cure for tendinopathy is selling something — not citing evidence.
Your physician in Cancún will quote the published numbers from the cited studies above, set realistic expectations in writing, and document follow-up so that response can be measured and the plan adjusted — not extrapolated from a brochure.
Patellar (Rodas et al., randomized vs PRP), Achilles (Goldberg et al., phase IIa safety + signal), and lateral epicondylitis (Lee et al., pilot of allogeneic adipose-derived MSC) have specific peer-reviewed clinical evidence cited on this page. The rotator cuff has growing evidence from cell-based therapies that is summarized in recent reviews; the picture is more mixed and is read case-by-case in evaluation. Other tendons are less studied — we'll tell you that, not pretend the evidence exists.
Your Regeneris physician in Cancún will give you a specific instruction set in writing — including whether to pause NSAIDs around the procedure, how to modify load and rehab, and when to resume eccentric loading. Most published protocols keep rehabilitation as a core part of the plan and adjust it around the injection rather than stopping it. There is no single template; the answer lives in your written protocol after the evaluation.
For focal chronic tendinopathy, the most studied route is intratendinous injection under real-time ultrasound guidance directly into the lesion, sometimes combined with surrounding fenestration. For broader cases or systemic regenerative goals, an intravenous protocol may be paired in. Whether the route is local, systemic, or both is a medical decision documented in your written quote — never a default. The procedure is in-office at our Cancún clinic, under physician supervision.
Because chronic tendinopathy is not a fixed product. Tendon, lesion size, prior treatments, cell source, dose, route, and follow-up depth all change a tendinopathy protocol — and so a published price would not be honest. Our model is a free medical evaluation, then a personalized written quote tailored to your case. That is true for every patient who reaches Regeneris in Cancún, México, regardless of where they fly in from.
Three reasons. Regulation — Regeneris operates under COFEPRIS Aviso Sanitario in Cancún, the same federal authority that regulates every legitimate medical procedure in México. Logistics — Cancún is one of the most-connected medical-tourism destinations from the U.S. and Canada, with direct flights from most major hubs. Clinical — our bilingual, physician-led Cancún team built the tendinopathy protocol around published evidence and individualized follow-up, not a marketing template. None of this substitutes for evidence; it makes the in-person evaluation realistically accessible.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS, laboratory certification, physician oversight, and traceability work in practice at a Cancún clinic.